Jonathan Schwartz - Feb 14, 2022 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical Officer & Clinical Development, SVP. Exhibit 24: Power of Attorney
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz
Stock symbol
RCKT
Transactions as of
Feb 14, 2022
Transactions value $
$0
Form type
4
Date filed
2/16/2022, 08:02 PM
Next filing
Apr 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +81K $0.00 81K Feb 14, 2022 Common Stock 81K $20.00 Direct F1
transaction RCKT Restricted Stock Units Award $0 +26K $0.00 26K Feb 14, 2022 Common Stock 26K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 81,010 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

Chief Medical Officer & Clinical Development, SVP. Exhibit 24: Power of Attorney